home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

61.63 +0.01 (+0.02%)

Streaming Delayed Price Updated: 10:56 AM EDT, Apr 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

HAEMONETICS CORP/MASS (NYSE:HAE) is probably undervalued for the fundamentals it is displaying. ↗

March 11, 2025

HAEMONETICS CORP/MASS has caught the attention as a great value stock. NYSE:HAE excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers

March 11, 2025

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.

Via StockStory

A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack

February 28, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best...

Via StockStory

(HAE) - Analyzing Haemonetics's Short Interest ↗

February 18, 2025

Via Benzinga

Haemonetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

February 07, 2025

Via Benzinga

Earnings Scheduled For February 6, 2025 ↗

February 06, 2025

Via Benzinga

How Is The Market Feeling About Haemonetics? ↗

January 31, 2025

Via Benzinga

The Latest Analyst Ratings For Haemonetics ↗

December 04, 2024

Via Benzinga

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect.

Via StockStory

Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect

February 09, 2025

Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know.

Via StockStory

For those who appreciate value investing, NYSE:HAE is a compelling option with its solid fundamentals. ↗

February 07, 2025

HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Haemonetics (NYSE:HAE) Misses Q4 Revenue Estimates

February 06, 2025

Blood products company Haemonetics (NYSE:HAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was...

Via StockStory

Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow

February 05, 2025

Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect.

Via StockStory

Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings) ↗

November 08, 2024

Via Benzinga

NYSE:HAE is not too expensive for the growth it is showing. ↗

October 31, 2024

While growth is established for NYSE:HAE, the stock's valuation remains reasonable.

Via Chartmill

Despite its growth, NYSE:HAE remains within the realm of affordability. ↗

October 10, 2024

HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued.

Via Chartmill

While growth is established for NYSE:HAE, the stock's valuation remains reasonable. ↗

December 13, 2024

For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering.

Via Chartmill

This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 06, 2024

Via Benzinga

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. ↗

November 21, 2024

In the world of growth stocks, NYSE:HAE shines as a value proposition.

Via Chartmill

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

September 24, 2024

From Aligos Therapeutics

Via GlobeNewswire

What Analysts Are Saying About Haemonetics Stock ↗

September 10, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 28, 2024

Looking for growth without the hefty price tag? Consider NYSE:HAE.

Via Chartmill

Analyst Expectations For Haemonetics's Future ↗

August 22, 2024

Via Benzinga

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

September 18, 2024

Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced.

Via Chartmill

Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗

August 16, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 06, 2024

Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSE:HAE).

Via Chartmill

Sotera Health Appoints Christopher Simon to the Board of Directors

August 01, 2024

From Sotera Health Services, LLC

Via GlobeNewswire

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

July 16, 2024

NYSE:HAE is not too expensive for the growth it is showing.

Via Chartmill

Looking for growth without the hefty price tag? Consider NYSE:HAE. ↗

June 25, 2024

HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank.

Via Chartmill

Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst ↗

June 12, 2024

Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com